This article is more than 5 years old. Information may no longer be current.

FDA grants tentative approval to lamivudine/zidovudine fixed-dose combination

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted tentative approval to a fixed-dose combination tablet that contains 30 mg lamivudine and 60 mg zidovudine, according to a press release.

The tablet — which is manufactured by Strides Arcolab Limited in Bangalore, India — is approved for use in combination with other antiretroviral therapy drugs for the treatment of HIV-1 infection.